To specify the role of immune/stromal cell-produced FGL2, we took advantage of Fgl2-deficient mice and injected them with either ovarian cancer (ID8-p53−/−Brca2−/−) or melanoma (B16F10) cells. This evidence concerns the gene TP53 and ovarian carcinoma.